Status:
COMPLETED
WT1 for the Detection of Minimal Residual Disease
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Conditions:
Leukemia
Cancer
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine if WT1 is an adequate measurement of minimal residual disease in leukemic patients.
Detailed Description
Patients with acute Leukemia may have a large number of leukemic cells at the time that leukemia is evident clinically. At the time that we determine that a patient is in complete remission (CR) the p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age less than 21 years of age.
- Patients with the following diseases: Acute lymphoblastic Leukemia (ALL) at the time of diagnoses or relapse, Acute non-lymphoblastic leukemia (ANLL) at diagnosis or after relapse and Chronic Myelogenous leukemia in chronic or accelerated phase.
- Patients will be eligible for any of the available treatment protocols or protocols for stem cell transplantation, regardless of the source of stem cells.
- Patients or legal guardians will sign an Institutional Review Board (IRB) approved informed consent.
- Patients will have venous access or peripheral vein for sampling.
Exclusion
Key Trial Info
Start Date :
February 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00179829
Start Date
February 1 1999
End Date
April 1 2006
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611